Peripheral blood HIV-1 DNA dynamics in antiretroviral-treated HIV/HCV co-infected patients receiving directly-acting antivirals
暂无分享,去创建一个
M. Capobianchi | A. Antinori | P. Lorenzini | A. Ammassari | G. Rozera | I. Abbate | A. Vergori | A. Amendola | L. Timelli | M. Zaccarelli | S. Cicalini | I. Mastrorosa | M. Plazzi | G. Fabbri
[1] V. Loustaud-Ratti,et al. European Association for the Study of the Liver and French hepatitis C recent guidelines: The paradigm shift , 2018, World journal of hepatology.
[2] G. Palù,et al. Time course of cellular HIV-DNA and low-level HIV viremia in HIV–HCV co-infected patients whose HCV infection had been successfully treated with directly acting antivirals , 2017, Medical Microbiology and Immunology.
[3] G. Fogel,et al. HIV DNA Is Frequently Present within Pathologic Tissues Evaluated at Autopsy from Combined Antiretroviral Therapy-Treated Patients with Undetectable Viral Loads , 2016, Journal of Virology.
[4] B. Clotet,et al. Short-term Treatment With Interferon Alfa Diminishes Expression of HIV-1 and Reduces CD4+ T-Cell Activation in Patients Coinfected With HIV and Hepatitis C Virus and Receiving Antiretroviral Therapy. , 2016, The Journal of infectious diseases.
[5] Trevor Bedford,et al. Persistent HIV-1 replication maintains the tissue reservoir during therapy , 2015, Nature.
[6] P. Messiaen,et al. HIV-1 RNA and HIV-1 DNA persistence during suppressive ART with PI-based or nevirapine-based regimens. , 2015, The Journal of antimicrobial chemotherapy.
[7] Nancie M Archin,et al. Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies. , 2015, The Journal of infectious diseases.
[8] David Rey,et al. Potential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected Patients , 2015, PloS one.
[9] C. Charpentier,et al. Levels of intracellular HIV-DNA in patients with suppressive antiretroviral therapy , 2015, AIDS.
[10] Rebecca J. Cope,et al. Majority of HIV/HCV Patients Need to Switch Antiretroviral Therapy to Accommodate Direct Acting Antivirals. , 2015, AIDS patient care and STDs.
[11] C. Rouzioux,et al. Impact of the Timing of Initiation of Antiretroviral Therapy During Primary HIV-1 Infection on the Decay of Cell-Associated HIV-DNA. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[12] Wei-jun Zhu,et al. Hepatitis C therapy with interferon-α and ribavirin reduces the CD4 cell count and the total, 2LTR circular and integrated HIV-1 DNA in HIV/HCV co-infected patients. , 2015, Antiviral research.
[13] J. Mellors,et al. HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[14] Eric Jullian,et al. Failure of combined antiretroviral therapy intensification with maraviroc and raltegravir in chronically HIV-1 infected patients to reduce the viral reservoir: the IntensHIV randomized trial , 2014, AIDS Research and Therapy.
[15] Xu G. Yu,et al. Hepatitis C therapy with interferon-α and ribavirin reduces CD4 T-cell-associated HIV-1 DNA in HIV-1/hepatitis C virus-coinfected patients. , 2014, The Journal of infectious diseases.
[16] N. Ciccarelli,et al. Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA , 2014, Journal of the International AIDS Society.
[17] D. Cooper,et al. HIV DNA Subspecies Persist in both Activated and Resting Memory CD4+ T Cells during Antiretroviral Therapy , 2014, Journal of Virology.
[18] C. Rouzioux,et al. Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts. , 2013, The Journal of antimicrobial chemotherapy.
[19] M. Carrington,et al. Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. , 2013, The Journal of infectious diseases.
[20] G. Pantaleo,et al. Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production , 2013, The Journal of experimental medicine.
[21] L. Montaner,et al. Concurrent measures of total and integrated HIV DNA monitor reservoirs and ongoing replication in eradication trials , 2012, AIDS.
[22] D. Cooper,et al. Switching Virally Suppressed, Treatment-Experienced Patients to a Raltegravir-Containing Regimen Does Not Alter Levels of HIV-1 DNA , 2012, PloS one.
[23] John W. Mellors,et al. No Effect of Raltegravir Intensification on Viral Replication Markers in the Blood of HIV-1–Infected Patients Receiving Antiretroviral Therapy , 2012, Journal of acquired immune deficiency syndromes.
[24] M. Capobianchi,et al. Standardization and performance evaluation of "modified" and "ultrasensitive" versions of the Abbott RealTime HIV-1 assay, adapted to quantify minimal residual viremia. , 2011, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[25] P. Narciso,et al. Effect of Raltegravir on the Total and Unintegrated Proviral HIV Dna during Raltegravir-Based Haart , 2011, Antiviral therapy.
[26] W. Bradford,et al. Danoprevir Monotherapy Decreases Inflammatory Markers in Patients with Chronic Hepatitis C Virus Infection , 2011, Antimicrobial Agents and Chemotherapy.
[27] Geneviève Boucher,et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation , 2009, Nature Medicine.
[28] P. Narciso,et al. Interferon may prevent HIV viral rebound after HAART interruption in HIV patients. , 2008, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[29] Olga M Klibanov,et al. Integrase Inhibitors: A New Treatment Option for Patients with Human Immunodeficiency Virus Infection , 2008, Pharmacotherapy.
[30] U. Pastorino,et al. Quantification of Free Circulating DNA As a Diagnostic Marker in Lung Cancer , 2003 .
[31] U. Pastorino,et al. Quantification of free circulating DNA as a diagnostic marker in lung cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] C. Rouzioux,et al. Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level , 2003, AIDS.
[33] M. Saag,et al. Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. , 1999, The Journal of clinical investigation.
[34] J. Lisziewicz,et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy , 1999, Nature Medicine.
[35] G. Salama,et al. Decay of HIV-1 DNA in patients receiving suppressive antiretroviral therapy. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
[36] J. Ball,et al. Evolutionary trends of the first hypervariable region of the hepatitis C virus E2 protein in individuals with differing liver disease severity. , 2002, The Journal of general virology.
[37] John L. Sullivan,et al. Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy , 2000, Nature Medicine.